AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38159337 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotiraciclib (TG02) with hypofractionated radiotherapy (group A)
Number of subjects: 0
Study 38159337 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotiraciclib (TG02) with temozolomide (group B)
Number of subjects: 0
Study 38159337 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 0
Study 38159652 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Number of subjects: 153
Study 38159652 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 153
Study 38159652 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 153
Study 38159652 — intervention group
Group type: COMPARATOR
Intervention: Anticonvulsants
Number of subjects: 153
Study 38159809 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pembrolizumab
Number of subjects: 623
Study 38159809 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus pembrolizumab
Number of subjects: 623
Study 38159908 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab treatment
Number of subjects: 60
Study 38159938 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary cytoreductive surgery followed by platinum based chemotherapy
Number of subjects: 400
Study 38159938 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 400
Study 38159941 — intervention group
Group type: EXPERIMENTAL
Intervention: active tDCS combined with Pilates-based exercises
Number of subjects: 36
Study 38159941 — intervention group
Group type: COMPARATOR
Intervention: sham tDCS combined with Pilates-based exercises
Number of subjects: 36
Study 38159942 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care combined with peer support (three individual sessions at 1, 3 and 5 months with a peer helper)
Number of subjects: 60
Study 38159942 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 60
Study 38159942 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care combined with peer support
Number of subjects: 60
Study 38159943 — intervention group
Group type: EXPERIMENTAL
Intervention: Human umbilical cord-derived mesenchymal stem cells (UC-MSCs)
Number of subjects: 0
Study 38159946 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive assessment of early organ damage
Number of subjects: 0
Study 38159946 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital follow-up mechanism
Number of subjects: 0
Study 38159946 — intervention group
Group type: EXPERIMENTAL
Intervention: Establishment of biological sample bank
Number of subjects: 0
Study 38159946 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of early structural and functional cardiovascular organ damage
Number of subjects: 0
Study 38159950 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional contact X-ray brachytherapy
Number of subjects: 168
Study 38159950 — intervention group
Group type: COMPARATOR
Intervention: Extended observation period followed by optional transanal local excision
Number of subjects: 168
Study 38159950 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 168
Study 38159958 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (CO-OP) intervention, consisting of 10 sessions.
Number of subjects: 20
Study 38160017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound estimation in the paramedian sagittal oblique (PSO) view
Number of subjects: 55
Study 38160017 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound estimation in the transverse median (TM) view
Number of subjects: 55
Study 38160017 — intervention group
Group type: EXPERIMENTAL
Intervention: Image quality of ligamentum flavum and posterior dura mater in PSO view
Number of subjects: 55
Study 38160047 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised yoga
Number of subjects: 125
Study 38160047 — intervention group
Group type: COMPARATOR
Intervention: iPad control
Number of subjects: 125
Study 38160049 — intervention group
Group type: EXPERIMENTAL
Intervention: HDM sublingual immunotherapy (SLIT)-tablets
Number of subjects: 742
Study 38160049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 742
Study 38160050 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative occupational exposure to gases/fumes
Number of subjects: 2042
Study 38160050 — intervention group
Group type: COMPARATOR
Intervention: Smoking
Number of subjects: 2042
Study 38160050 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative occupational exposure (gases/fumes)
Number of subjects: 2042
Study 38160050 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational exposures (in women)
Number of subjects: 2042
Study 38160050 — intervention group
Group type: COMPARATOR
Intervention: Smoking (in women)
Number of subjects: 2042
Study 38160357 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 20
Study 38160619 — intervention group
Group type: EXPERIMENTAL
Intervention: PROTAC technology
Number of subjects: 0
Study 38160619 — intervention group
Group type: EXPERIMENTAL
Intervention: Controllable PROTACs
Number of subjects: 0
Study 38160756 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin calcium (4 mg/day) for 180 days
Number of subjects: 12
Study 38160802 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 15
Study 38160802 — intervention group
Group type: EXPERIMENTAL
Intervention: WFPB diet
Number of subjects: 15
Study 38160802 — intervention group
Group type: COMPARATOR
Intervention: Baseline diet
Number of subjects: 15
Study 38160802 — intervention group
Group type: COMPARATOR
Intervention: FAFH costs for baseline diet
Number of subjects: 15
Study 38160802 — intervention group
Group type: COMPARATOR
Intervention: FAFH costs for DASH diet
Number of subjects: 15
Study 38160802 — intervention group
Group type: EXPERIMENTAL
Intervention: FAFH costs for WFPB diet
Number of subjects: 15
Study 38160805 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea protein
Number of subjects: 15
Study 38160805 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein
Number of subjects: 15
Study 38160885 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine treatment for 4 weeks
Number of subjects: 98
Study 38160885 — intervention group
Group type: COMPARATOR
Intervention: Baseline abnormal ReHo
Number of subjects: 98
Study 38160916 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time tracking/gating during MRgRT
Number of subjects: 79
Study 38160917 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg subcutaneously every 2 weeks
Number of subjects: 12301
Study 38160917 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 12301
Study 38161174 — intervention group
Group type: EXPERIMENTAL
Intervention: Feelings of vulnerability
Number of subjects: 373
Study 38161174 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of fear of dying
Number of subjects: 373
Study 38162283 — intervention group
Group type: COMPARATOR
Intervention: Community-based delivery of HIV services including testing, antiretroviral therapy, treatment monitoring and adherence support, family planning, syndromic management of STIs, menstrual health management, condoms, and HIV prevention and general health counselling.
Number of subjects: 24
Study 38162439 — intervention group
Group type: EXPERIMENTAL
Intervention: Myasthenia gravis patients
Number of subjects: 1660
Study 38162439 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 1660
Study 38162453 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly subcutaneous galcanezumab 300 mg
Number of subjects: 343
Study 38162453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study 38162451 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine-based DOAC dipstick test
Number of subjects: 23
Study 38162492 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) + Temozolomide (TMZ)
Number of subjects: 41
Study 38162492 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide (TMZ) alone (standard treatment)
Number of subjects: 41
Study 38162801 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiglitazar
Number of subjects: 81
Study 38162801 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 81
Study 38162999 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g sustained-release L-arginine 3 times/d (4.5 g/d) for 4 weeks
Number of subjects: 32
Study 38162999 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 32
Study 38163294 — intervention group
Group type: EXPERIMENTAL
Intervention: Exoskeleton-assisted walking program (16-week duration, 34 individualized 1-hour sessions, progressing from 1 to 3 sessions per week)
Number of subjects: 10
Study 38163294 — intervention group
Group type: EXPERIMENTAL
Intervention: Exoskeleton-assisted walking program
Number of subjects: 10
Study 38163317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFCR) followed by 2-year ibrutinib maintenance (I-M)
Number of subjects: 85
Study 38163317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib maintenance (I-M)
Number of subjects: 85
Study 38163317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib retreatment
Number of subjects: 85
Study 38163317 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (iFCR with 2-year I-M)
Number of subjects: 85
Study 38163318 — intervention group
Group type: EXPERIMENTAL
Intervention: LMP-TCs (third-party latent membrane protein-specific T cells)
Number of subjects: 15
Study 38163481 — intervention group
Group type: EXPERIMENTAL
Intervention: VAP-specific bundled diagnostic stewardship intervention (VAP-DSI)
Number of subjects: 0
Study 38163530 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral Epicondylitis Band (LEB)
Number of subjects: 159
Study 38163530 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist Extensor Splint (WES)
Number of subjects: 159
Study 38163530 — intervention group
Group type: COMPARATOR
Intervention: Education-only (wait-and-see)
Number of subjects: 159
Study 38163585 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks for up to 144 weeks (∼3 years)
Number of subjects: 393
Study 38163904 — intervention group
Group type: EXPERIMENTAL
Intervention: Needs-based communication skills training for nursing professionals
Number of subjects: 180
Study 38163904 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control group
Number of subjects: 180
Study 38163912 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for soil-transmitted helminth infections (STH)
Number of subjects: 262
Study 38163943 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with obstructive sleep apnea who developed major adverse cardiac and cerebrovascular events (n = 115)
Number of subjects: 1007
Study 38163943 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller ΔQTc
Number of subjects: 1007
Study 38163943 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher preoperative oxygen desaturation index
Number of subjects: 1007
Study 38163943 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔQTc within 24 hours after CABG
Number of subjects: 1007
Study 38164417 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGylated urate oxidase
Number of subjects: 56
Study 38164417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 38164441 — intervention group
Group type: EXPERIMENTAL
Intervention: FUEL intervention consisting of weekly online lectures and individual athlete-centered nutrition counseling every other week for sixteen weeks.
Number of subjects: 0
Study 38164586 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioligand therapy agent (specific agent not mentioned)
Number of subjects: 0
Study 38164752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 9336
Study 38164752 — intervention group
Group type: COMPARATOR
Intervention: Control (standard blood pressure treatment)
Number of subjects: 9336
Study 38164757 — intervention group
Group type: EXPERIMENTAL
Intervention: XTX101 monotherapy
Number of subjects: 0
Study 38164757 — intervention group
Group type: EXPERIMENTAL
Intervention: XTX101 in combination with anti-PD-1 mAb
Number of subjects: 0
Study 38164982 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH-score
Number of subjects: 2195
Study 38164982 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary calcium intake from DASH food groups
Number of subjects: 2195
Study 38164982 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary calcium intake from non-DASH food groups
Number of subjects: 2195
Study 38164982 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary magnesium intake from DASH food groups
Number of subjects: 2195
Study 38164982 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary magnesium intake from non-DASH food groups
Number of subjects: 2195
Study 38165016 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) treatment combined with zoledronic acid (ZA)
Number of subjects: 26
Study 38165016 — intervention group
Group type: COMPARATOR
Intervention: Control group (h-HSCT only)
Number of subjects: 26
Study 38165027 — intervention group
Group type: EXPERIMENTAL
Intervention: m-health tool (pre-programmed tablet with weighing scale and interactive education about HF self-care)
Number of subjects: 71
Study 38165278 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention, 6 sessions
Number of subjects: 70
Study 38165278 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 70
Study 38165296 — intervention group
Group type: EXPERIMENTAL
Intervention: Aducanumab
Number of subjects: 1681
Study 38165324 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI/MRA
Number of subjects: 405
Study 38165324 — intervention group
Group type: COMPARATOR
Intervention: CT/CTA
Number of subjects: 405
Study 38165333 — intervention group
Group type: EXPERIMENTAL
Intervention: IV nipocalimab 5 mg/kg Q4W
Number of subjects: 68
Study 38165333 — intervention group
Group type: EXPERIMENTAL
Intervention: IV nipocalimab 30 mg/kg Q4W
Number of subjects: 68
Study 38165333 — intervention group
Group type: EXPERIMENTAL
Intervention: IV nipocalimab 60 mg/kg Q2W
Number of subjects: 68
Study 38165333 — intervention group
Group type: EXPERIMENTAL
Intervention: IV nipocalimab 60 mg/kg single dose
Number of subjects: 68
Study 38165333 — intervention group
Group type: COMPARATOR
Intervention: IV placebo Q2W
Number of subjects: 68
Study 38165335 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerinetide
Number of subjects: 67
Study 38165335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 38165678 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance with the study protocol
Number of subjects: 0
Study 38165678 — intervention group
Group type: COMPARATOR
Intervention: Sham-control group
Number of subjects: 0
Study 38165683 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa 2,400 mg once every 3 weeks plus cisplatin or carboplatin plus paclitaxel with bevacizumab (Cohort 1A)
Number of subjects: 25
Study 38165683 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa 2,400 mg once every 3 weeks plus cisplatin or carboplatin plus paclitaxel without bevacizumab (Cohort 1B)
Number of subjects: 25
Study 38165683 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa 2,400 mg every 3 weeks plus cisplatin plus radiation, followed by bintrafusp alfa monotherapy maintenance (Cohort 2)
Number of subjects: 25
Study 38165964 — intervention group
Group type: EXPERIMENTAL
Intervention: TRIMOSH intervention
Number of subjects: 240
Study 38165964 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 240
Study 38165970 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month lifestyle intervention based on psychological counseling, nutrition, and exercise
Number of subjects: 30
Study 38166036 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-formulated ketogenic diet (WFKD)
Number of subjects: 20
Study 38166187 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantum molecular resonance treatment with Rexon-Eye device, once per week for 4 weeks
Number of subjects: 40
Study 38166187 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study 38166187 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 38166346 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CT angiography-based index (α×LL/MLD)
Number of subjects: 0
Study 38166598 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketofol (ketamine: propofol 1:4)
Number of subjects: 120
Study 38166598 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 120
Study 38166598 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 0.9% (Control group)
Number of subjects: 120
Study 38166598 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketofol
Number of subjects: 120
Study 38166598 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 38166598 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergence agitation and high-dose opioid consumption
Number of subjects: 120
Study 38166634 — intervention group
Group type: EXPERIMENTAL
Intervention: SGB with 0.5% ropivacaine (group S)
Number of subjects: 58
Study 38166634 — intervention group
Group type: COMPARATOR
Intervention: SGB with 0.9% saline (group N)
Number of subjects: 58
Study 38166647 — intervention group
Group type: COMPARATOR
Intervention: Regorafenib monotherapy
Number of subjects: 537
Study 38166647 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib combined with immune-checkpoint inhibitors
Number of subjects: 537
Study 38166676 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body head-up tilt sleeping (HUTS) at 6°, 12°, and 18°
Number of subjects: 50
Study 38166676 — intervention group
Group type: COMPARATOR
Intervention: Placebo angle (1°) followed by 6° and 12°
Number of subjects: 50
Study 38166676 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body head-up tilt sleeping (HUTS)
Number of subjects: 50
Study 38166677 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in Bavarian Research Practice Network (BayFoNet)
Number of subjects: 20
Study 38166677 — intervention group
Group type: COMPARATOR
Intervention: Non-participation in Bavarian Research Practice Network (BayFoNet)
Number of subjects: 20
Study 38166677 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitators for participation
Number of subjects: 20
Study 38166677 — intervention group
Group type: COMPARATOR
Intervention: Barriers for participation
Number of subjects: 20
Study 38166698 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib alone
Number of subjects: 25
Study 38166698 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib + Bevacizumab (Bev)
Number of subjects: 25
Study 38166710 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 1000 mg IV every 12 hours
Number of subjects: 22
Study 38166710 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C concentrations
Number of subjects: 22
Study 38166746 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangible support from lay healthcare supporters (LHSs)
Number of subjects: 17
Study 38166746 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional support from mental health professionals (MPs)
Number of subjects: 17
Study 38166746 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up interventions
Number of subjects: 17
Study 38166746 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated mental health care service network
Number of subjects: 17
Study 38166746 — intervention group
Group type: EXPERIMENTAL
Intervention: Community instrumental support
Number of subjects: 17
Study 38166746 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring and non-discriminatory environment
Number of subjects: 17
Study 38166780 — intervention group
Group type: EXPERIMENTAL
Intervention: Living alone group
Number of subjects: 8307
Study 38166780 — intervention group
Group type: COMPARATOR
Intervention: Not living alone group
Number of subjects: 8307
Study 38166797 — intervention group
Group type: EXPERIMENTAL
Intervention: #LIFEGOALS mobile health intervention
Number of subjects: 279
Study 38166797 — intervention group
Group type: COMPARATOR
Intervention: No intervention group
Number of subjects: 279
Study 38166834 — intervention group
Group type: EXPERIMENTAL
Intervention: Biobased polyester cast
Number of subjects: 100
Study 38166834 — intervention group
Group type: COMPARATOR
Intervention: Synthetic fiberglass cast
Number of subjects: 100
Study 38166851 — intervention group
Group type: EXPERIMENTAL
Intervention: Facing Your Fears-School Based (FYF-SB)
Number of subjects: 200
Study 38166851 — intervention group
Group type: COMPARATOR
Intervention: Zones of Regulation (ZOR)
Number of subjects: 200
Study 38166864 — intervention group
Group type: EXPERIMENTAL
Intervention: Harm reduction approach
Number of subjects: 89
Study 38166864 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered communication incorporating the harm reduction model
Number of subjects: 89
Study 38166894 — intervention group
Group type: EXPERIMENTAL
Intervention: Mantram Repetition Program (virtual, 90 minutes, 8 weeks duration)
Number of subjects: 43
Study 38166894 — intervention group
Group type: EXPERIMENTAL
Intervention: Mantram Repetition Program
Number of subjects: 43
Study 38166913 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (Acetazolamide plus Rapid-Ripc)
Number of subjects: 250
Study 38166913 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (twice daily, 2 days)
Number of subjects: 250
Study 38166913 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid-Ripc (RIPC four times daily, 3 days)
Number of subjects: 250
Study 38166913 — intervention group
Group type: EXPERIMENTAL
Intervention: Ripc (RIPC twice daily, 6 days)
Number of subjects: 250
Study 38166913 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 250
Study 38166991 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual estimation by surgeons
Number of subjects: 61
Study 38166991 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual estimation by anesthesiologists
Number of subjects: 61
Study 38166991 — intervention group
Group type: EXPERIMENTAL
Intervention: Gravimetric method
Number of subjects: 61
Study 38166991 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculation method (López-Picado's formula)
Number of subjects: 61